
|Articles|December 1, 2002
Nomogram for predicting PCa recurrence is validated
New York-A computer model nomogram that uses three preoperative prostate cancer variables to predict probabilities for cancer recurrence within 5 years has been successfully validated. The nomogram will not only aid physicians in making treatment decisions, but it could also help improve patients' ability to make decisions about their treatment, according to researchers from Memorial Sloan-Kettering Cancer Center in New York.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
2
Farah Rahman, MD, on monitoring resident wellness using biofeedback
3
Pearls & Perspectives: Innovation and Evolving Pathways in Female Pelvic Medicine, with Raveen Syan, MD, FPMRS
4
Veda Giri, MD, on patient-reported outcomes with prostate cancer genetic testing
5






